EVELO BIOSCIENCES INC (EVLO)

What's going on in today's after hours session

The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

The biggest pre-market stock movers are a hot topic traders are going to want to know about with all the latest news on Friday!

Why Is Impinj (PI) Stock Down 25% Today?

Impinj (PI) stock is falling on Thursday after the radio-frequency chipmaker released its earnings report for the first quarter of 2023.

Why Is Baudax Bio (BXRX) Stock Down 52% Today?

Baudax Bio (BXRX) stock is falling hard on Thursday after the pharmaceutical company announced a $4 million public stock offering.

Why Is Atomera (ATOM) Stock Up 34% Today?

Atomera (ATOM) stock is taking off on Thursday following the release of its earnings report for the first quarter of 2023!

Why Is Evelo Biosciences (EVLO) Stock Up 78% Today?

Evelo Biosciences (EVLO) stock is on the rise Thursday after the company said it's shifting focus toward EV development.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

The biggest pre-market stock movers are ready to go as we dive into the latest news traders need to know about on Thursday!

Evelo stock falls as eczema drug abandoned after trial fails; cuts staff

Evelo Biosciences (EVLO) said it will stop development of EDP1815 in atopic dermatitis (eczema) after the drug failed a trial. Read more here

Evelo Biosciences Provides Clinical Updates

Evelo Biosciences Provides Clinical Updates

– Topline Data from fourth cohort of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint –– Company will focus on development of...

Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), (“Evelo” or the “Company”) a clinical stage biotechnology...

Friday Sector Laggards: Biotechnology, Drugs

Evelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023

Evelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023

CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel...

Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care Conference

Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial

Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial

– Completed first blinded, placebo-controlled cohort in human volunteers with no safety or tolerability concerns – – Dosing in EDP2939 Phase 2 trial in...

EVLO stock drops as atopic dermatitis trial fails; announces layoffs (NASDAQ:EVLO)

Clinical-stage biotech Evelo Biosciences (EVLO) lost ~23% pre-market Wednesday after announcing staff reductions and failure for an atopic dermatitis candidate. Read the full story here.

Evelo Biosciences Provides Clinical and Business Updates

Evelo Biosciences Provides Clinical and Business Updates

– Data from first three cohorts of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint; unusually high placebo response rate observed...

Horizon Technology Finance Provides Fourth Quarter 2022 Portfolio Update

/PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ: HRZN) ("HRZN" or the "Company"), a leading specialty finance company that provides capital in...